您的位置: 首页 > 农业专利 > 详情页

The quick foundation and/or termination of basic steady-state drug delivery
专利权人:
INTARCIA THERAPEUTICS, INC.;精達製藥公司;精达制药公司
发明人:
T.R.阿莱西,T.R.阿萊西,K.L.卢斯基,K.L.盧斯基
申请号:
MOJ003679
公开号:
MOJ003679B
申请日:
2019.05.10
申请国别(地区):
MO
年份:
2019
代理人:
摘要:
The present invention relates to the treatment methods of the disease or symptom that are needed in the subject of such treatment with what, it provides the substitution to what by the treatment of injection, opposite what is by the treatment of injection, and the treatment method provides improved treatment results, 100% treatment is complied with, the quick foundation and/or termination of the side effect of reduction and basic steady-state drug delivery. The drug that this method generally comprises osmotic delivery device of the offer from implantation continuously delivers, wherein implantable osmotic delivery apparatus Hou is interior at about 7 days or less in subject, drug is commonly reached with the basic steady-state delivery for the treatment of concentration, and the basic steady-state delivery of drug from osmotic delivery device in the period of by least about 3 months in be continuous. In one embodiment, the present invention relates to use the diabetes B of duodenin analogies to treat.本發明涉及用於需要此類治療的受試者中的疾病或病狀的治療方法,其提供對於通過注射的治療的替代,相對於通過注射的治療,所述治療方法給出改善的治療結果、100%治療順應、減少的副作用、和基本穩態藥物遞送的快速建立和/或終止。該方法一般包括提供來自植入的滲透遞送裝置的藥物連續遞送,其中在受試者中植入滲透遞送裝置後在約7天或更少內,一般達到藥物以治療濃度的基本穩態遞送,並且來自滲透遞送裝置的藥物基本穩態遞送在經過至少約3個月的時期內是連續的。在一個實施方案中,本發明涉及使用腸降血糖素模擬物的2型糖尿病治療。
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充